Skip to content

LIMINATUS PHARMA, INC.

LIMN LIMNW

CIK 0001971387

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$3.16M
−187.8% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.12
−115.0% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$9.98M
Q1 May 2026
Cash
$0
Q1 May 2026
Total Debt
$1.44M
Q1 May 2026
Shares Outstanding
44.88M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Recent filings